CHF7.25
1.23% yesterday
SIX Swiss Exchange, Jun 13, 05:31 pm CET
ISIN
IT0004147952
Symbol
NWRN
Sector
Industry

Newron Pharmaceutical Stock price

CHF7.25
-0.92 11.26% 1M
-1.95 21.20% 6M
-1.70 18.99% YTD
-2.69 27.06% 1Y
+5.44 300.55% 5Y
-17.60 70.82% 10Y
-45.85 86.35% 20Y
SIX Swiss Exchange, Closing price Fri, Jun 13 2025
-0.09 1.23%
ISIN
IT0004147952
Symbol
NWRN
Sector
Industry

Key metrics

Market capitalization CHF151.70m
Enterprise Value CHF189.88m
P/E (TTM) P/E ratio 9.18
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.93
P/S ratio (TTM) P/S ratio 3.14
P/B ratio (TTM) P/B ratio 107.00
Revenue growth (TTM) Revenue growth 467.61%
Revenue (TTM) Revenue CHF48.19m
EBIT (operating result TTM) EBIT CHF24.54m
Free Cash Flow (TTM) Free Cash Flow CHF-16.53m
Cash position CHF9.21m
EPS (TTM) EPS CHF0.80
P/E forward negative
P/S forward 8.77
EV/Sales forward 10.97
Show more

Is Newron Pharmaceutical a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,847 stocks worldwide.

Newron Pharmaceutical Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Newron Pharmaceutical:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Newron Pharmaceutical:

Buy
100%

Financial data from Newron Pharmaceutical

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
48 48
468% 468%
100%
- Direct Costs 0.84 0.84
91% 91%
2%
47 47
488% 488%
98%
- Selling and Administrative Expenses 11 11
55% 55%
22%
- Research and Development Expense 12 12
1% 1%
25%
25 25
331% 331%
51%
- Depreciation and Amortization 0.18 0.18
5% 5%
0%
EBIT (Operating Income) EBIT 25 25
325% 325%
51%
Net Profit 15 15
198% 198%
31%

In millions CHF.

Don't miss a Thing! We will send you all news about Newron Pharmaceutical directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

Newron Pharmaceuticals SpA operates as a biopharmaceutical company. It focuses on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The firm's products include Xadago (safinamide), Evenamide (NW-3509) and Ralfinamide. The company was founded by Luca Benatti, Ruggero Fariello and Patricia Salvati in 1999 and is headquartered in Bresso, Italy.

Head office Italy
CEO Stefan Weber
Employees 22
Founded 2002
Website www.newron.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today